CAR-T and Immune Aging: Why T Cell Quality Matters

In 2017, the FDA approved the first drug of its kind in medicine: Kymriah, a CAR-T therapy for leukemia in children. The idea is simple and revolutionary at the same time. A patient's own T cells are taken, engineered in the lab to recognize a specific protein on the surface of cancer cells, multiplied into billions, and returned to the body. Within weeks, the engineered cells eliminate the cancer.

The results were dramatic: about 80% overall response rate in children and young adults with acute lymphoblastic leukemia (ALL) resistant to all other treatments. By 2024, there were already 6 approved CAR-T therapies, most for leukemia and lymphoma. But beneath the clinical euphoria, a troubling question remained open: why does the treatment work excellently for some patients and fail for others?

For years, it was thought to be solely a matter of age. But new research from Rutgers University, published in the journal Cell Reports in early 2026 (the press release was published in April 2026), offers a more precise explanation: what determines success is the quality of the T cells extracted from the patient, and more specifically, how many of them are in a state of senescence (cellular aging). Age correlates with cell quality, but it does not determine it alone. This places immune aging at the center of advanced cancer medicine.

What exactly is CAR-T therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. The steps:

• Apheresis: Blood is drawn from the patient, and T cells (a type of leukocyte) are isolated from it.
• Genetic engineering: Using a viral vector, a gene encoding a chimeric receptor is inserted into the cells. This receptor consists of an external part that recognizes a specific protein on cancer cells (e.g., CD19 in leukemia and lymphoma), and an internal part that activates the cell.
• Expansion: The engineered cells are grown in the lab for several days. Billions of cells are needed.
• Preparative treatment: The patient receives mild chemotherapy (lymphodepletion) that empties the immune system and prepares the body for the new cells.
• Reinfusion: The engineered cells are returned to the bloodstream. They recognize the cancer and eliminate it.

Success depends critically on the quality of the cells extracted. If they are healthy, energetic, and have a young profile, they will multiply quickly in the lab and become a mighty army in the body. If a large portion of them are senescent and exhausted, they will not multiply well in the lab, and in the body, they will live too short a time to effectively eliminate the cancer.

What are exhausted T cells?

An exhausted T-cell is a functional state well-known in immunology. It is created when the cell is exposed to an antigen for a prolonged period, months or years. In this state, it:

• Loses the ability to proliferate. An exhausted cell hardly divides. (To be precise: the Hayflick limit of about 50 divisions was originally described in fibroblast cells in the lab, not in T cells; in T cells, cellular senescence is mainly expressed in loss of division and response ability.)
• Expresses inhibitory receptors like PD-1, TIM-3, LAG-3, which halt the immune response.
• Secretes fewer cytokines (IL-2, IFN-gamma) needed to coordinate an immune response.
• Acquires a unique epigenetic signature, marking it as a limited cell.

In an older person, many T cells tend to be in an exhausted or senescent state at a higher frequency. They have been exposed over a lifetime to chronic infections (CMV, EBV), chemotherapy, recurrent infections. Each such stimulus left an exhausted signature. But even among older adults, variability is high, and some maintain T cells with a young profile.

The connection to aging: immunosenescence

The broader phenomenon underlying exhausted T cells is called immunosenescence, immune senescence. This is the professional term for the immune system aging at an accelerated rate relative to other parts of the body. The characteristics:

1. Thymic involution

The thymus gland is the T cell production factory. It is active in childhood and adolescence, begins to shrink even during adolescence, and largely atrophies with age. The less active the thymus, the fewer new (naive) T cells the body produces, relying more and more on an existing pool of cells.

2. Decreased receptor diversity

A young person holds a very rich repertoire of naive T cell receptors, each recognizing a unique antigen. With age, the diversity of the naive repertoire shrinks, and the body finds it harder to mount a new response to antigens it hasn't encountered before, including new tumor antigens.

3. Accumulation of senescent cells

Senescent T cells accumulate in the blood of older adults. Instead of helping, many secrete SASP (Senescence-Associated Secretory Phenotype), inflammatory substances that poison the environment. They can impair the overall function of the immune system.

4. Metabolic disruptions

Old T cells often suffer from impaired mitochondrial function. They struggle to produce the energy needed for proliferation and attack. In the lab, they appear sluggish, and in the body, they operate heavily.

Current evidence: what the research actually found

The main study: Rutgers, Cell Reports 2026

The study, led by the lab of Dr. Ricardo Ivan Martinez-Zamudio at Rutgers University, was published in the journal Cell Reports (online in early 2026; the press release came out in April 2026). It is important to clarify what the study actually did, because inaccurate descriptions circulated online:

• The researchers took blood from young and old donors, isolated CD8+ T cells, sorted them into senescent and non-senescent cells, and mapped the gene expression and chromatin landscape (epigenetic) of each group.
• They did not conduct a prospective study on 1,800 patients across 5 centers. Instead, they took the gene signatures of senescent cells and examined them against previously published clinical data of lymphoma (DLBCL) patients who underwent CAR-T.

The main finding: The senescence signature of CD8+ T cells predicted the response to CAR-T therapy. Patients whose starting cells and final product carried a strong senescence signature were more likely to fail treatment; patients with a younger profile were more likely to respond. Additionally, the study identified networks of transcription factors (AP1, KLF5, RUNX2) that drive the senescence program, and inhibiting them partially restored the response of senescent T cells to stimulation. Interestingly: these networks operated similarly in young and old individuals, meaning senescence itself (and not chronological age per se) is the central mechanism.

The researchers emphasized that the clinical analysis is retrospective and needs prospective confirmation, and they plan to test whether mapping senescence before CAR-T cell production can predict who will respond to treatment.

Important clarification: Does CAR-T really fail in older adults?

Caution is needed here. Real-world data show that CAR-T is also effective in older adults. Complete response rates in those aged 70 and over are similar to those of younger patients, and even in patients aged 80 and over, complete response rates around 50% have been reported, with the treatment found safe and feasible. That is, there is no blanket failure in older adults. The precise message of the study is that the quality of T cells (degree of senescence) predicts the response, and this is a variable correlated with age but not determined solely by it. This is a critical distinction: it opens the possibility of identifying in advance who is at risk for a weak response, without disqualifying any patient based on age alone.

Research directions for improving cell quality

Alongside the Rutgers work, research directions are developing that attempt to improve T cell quality before or during engineering. It is important to note: most are still early, pre-clinical, or in initial trial stages without final results:

• Metabolic reprogramming (pre-clinical): Lab work and animal models show that improving the mitochondrial function of CAR-T cells (e.g., by enhancing mitochondrial biogenesis and cellular metabolism) can increase their persistence in the body and reduce exhaustion. These are promising findings but have not yet been proven in humans.
• Senolytics combined with CAR-T (active clinical trial, no results yet): At Mayo Clinic, a phase 2 trial (NCT06940297, named DART) is currently running, examining the combination of dasatinib + quercetin (a senolytic cocktail) with CAR-T therapy in patients with refractory multiple myeloma. The trial is recruiting participants and no results have been published yet, so it is not yet known if it improves the response.

Beyond CAR-T: implications for vaccines and the immune system in general

The principle of T cell quality may explain other phenomena in immune aging:

• Flu vaccines are less effective in older adults. Exhausted T cells form poorer immune memory. This is one reason a high-dose vaccine is recommended for ages 65+.
• Checkpoint inhibitor therapies (Keytruda, Opdivo) are less effective when T cells are already highly exhausted, because opening the checkpoint alone is not enough.
• Increased susceptibility to infections in old age, even when the system "exists on paper."
• Weaker response to vaccines in older adults, even after boosters.

The connection is clear: T cell quality affects the quality of the immune response in many contexts, from cancer to infections. If we can preserve or improve cell quality, it has implications beyond oncology.

Can we slow immune aging?

This is the real excitement of the field. Directions currently being investigated (at varying levels of maturity):

1. Thymic regeneration

Researchers led by Intervene Immune tested whether a combination of growth hormone, dehydroepiandrosterone (DHEA), and metformin could regenerate the thymus. In the small TRIIM study in 2019 (9 male volunteers), signs of thymic regeneration and a decrease of about 2.5 years in the epigenetic clock were reported. This is a small and preliminary study, and a larger follow-up trial was planned.

2. CAR-T from a young donor (allogeneic)

Instead of using the patient's T cells, use T cells from a young, healthy donor. The barrier: graft rejection. Solutions like CRISPR editing to remove HLA receptors are in development and clinical trials, with companies like Allogene Therapeutics leading the field.

3. T cells from pluripotent stem cells (iPSC)

In this approach, stem cells are created from skin or blood cells, reprogrammed, and then new T cells are grown from them. The goal: a uniform set of cells without the patient's accumulated aging. Companies like Fate Therapeutics (with product FT819) and Century Therapeutics are working on this line.

4. Targeting senescent cells

As the senescence signature is better understood, the possibility opens to identify and target senescent cells, or inhibit the transcription factors that drive senescence (as the Rutgers work showed in the lab). This is still a research direction, not an available treatment.

What to take from the research?

If you are young and healthy, the following recommendations support keeping your T cells in good shape over time:

1. Treat chronic infections: Gingivitis, active CMV, EBV. Every chronic infection burdens the immune system over time.
2. Avoid processed foods that trigger chronic inflammation. Inflammation is a stimulus that exhausts T cells.
3. Maintain a healthy weight: Visceral fat secretes inflammatory cytokines.
4. Engage in regular physical activity. Aerobic activity reduces inflammation and supports immune function.
5. Quality sleep (7-9 hours). This is when the immune system performs maintenance.
6. If you are over 60, talk to your doctor about immune system health as part of general monitoring.

The broader perspective

The story of T cell quality in CAR-T illuminates a deep principle in aging medicine: our new technologies depend on the state of the patient's immune system. Not only CAR-T, but also vaccines, immunotherapy, and transplants all work better on a well-functioning immune system.

This places immune aging at the center of tomorrow's medicine. In some cases, it may be worthwhile to check and improve T cell quality before advanced treatment. Directions like targeting senescence, metabolic reprogramming, and thymic regeneration are being researched now, but it is important to remember that most are still research-based and not approved treatments.

Ultimately, the question is not only how we fight cancer, but how we maintain the army that needs to fight it. The better we understand what keeps T cells young and effective, the more we will improve not only cancer treatment but the entire defense system of the body.

References:
Turano et al., Cell Reports 2026 - Age-independent and targetable transcription factor networks regulating CD8+ T cell senescence in aging humans
Rutgers University - Why Cell Therapy Cancer Treatment Sometimes Fails
National Cancer Institute - CAR T-cell Therapy